Project Description

The OASIS project aims to improve the links between life science facilities, research projects and product development. Thanks to OASIS, the previous large investments in biophotonics will be more accessible to SMEs to allow a competitive advantage in new products development and validation.

Open life science infrastructures to SMEs

Large scale research facilities and technology platforms are usually sets of laboratory equipments that are mainly available to academics and to a certain extent to industrials. They can be very large-scale equipment, unique to a country or a continent as well as technological hall shared by a wide scientific and technological community, which develops competencies in a specific area.

In the field of the life sciences, the management of open access for researchers and world-class research programmes between these facilities is under consolidation through existing programmes like Instruct, EuroBioimaging... Large companies have established strong collaborations with these facilities but there is still room for improving their economic outputs and the involvement of SMEs in order to create more value and jobs from early scientific results

Two grand societal challenges of our time adressed by OASIS: "Healthcare in an Aging Society" and "Agri-Food Safety and security for Europe's citizens"

Clusters to help SMEs to reach biophotonic markets

Photonics clusters and national platforms, strong links between Science and Economy, as well as between regional and international environments, will play a key role in organizing the collaboration between these life science facilities and the European SMEs.

The seven European countries involved in the project (France, UK, Germany, Sweden, Netherlands, Italy, Spain) gathered 70% of the new infrastructures in Life Sciences in FP7. Nine photonics clusters from these countries, involved in initiatives supporting Biophotonics at the regional or national level are active in the OASIS Support Action.

The consortium will first inventory and geographically map the former European investments made in Photonics Life Science facilities, to make them more easily accessible to SMEs. It will also inventory the relevant companies and their needs in terms of lab infrastructures, and will try to identify some needs from medical and agri-food actors that might be solved with photonics technologies.

Targeting the right facilities is a prerequisite for efficient innovation and the right definition of collaborations can be a real challenge. OASIS partners will design services to improve collaboration frameworks between facilities, SMEs, hospitals, industrials, for product developments and validation.

Last but not least, financing transfer and initial deployment is still a challenge in these highly regulated markets, the so called “valley of death”. OASIS will promote these technologies and their economic interest toward financing community.

 


Agri-food sensor

Ocular surgery

The actions of OASIS will bring to European SMEs a competitive advantage in new products development and validation. They will also help them to get faster access to their markets by increasing available funding on these technologies and by reducing both cost and time through re-use of former investments.

 

Objective will be to significantly reduce time to market (currently between 5 and 15 years) for new imaging or sensing modalities.

Outcomes will be delivered through a set of public deliverables in the form of one handbook compiling success stories in the field of biophotonics, a website with a map of biophotonics facilities, flyers and a range of dissemination activities targeting all key stakeholders. Another activity will be to continuously prepare, update and spread information materials in the form of presentations targeting different audiences, short articles and press releases to be included in others’ dissemination channels. Beyond the 9 clusters in the consortium, the final objective is to spread tools and services towards others clusters and European facilities.

 

.